Orlistat associated subacute hepatic failure [1]

Journal of Hepatology

Volumn 34, Issue 1, 2001, Pages 173-

  Montero, José Luis ^a   Muntané, Jordi ^a   Fraga, Enrique ^a   Delgado, Manuel ^a   Costán, Guadalupe ^a   Serrano, Manuel ^a   Padillo, Javier ^b   De la Mata, Manuel ^a   Mio, Gonzalo ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b Hosp Univ Ciudad de Jaén   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

TETRAHYDROLIPSTATIN;

ADULT; BLOOD CHEMISTRY; CASE REPORT; DIAGNOSTIC IMAGING; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; HUMAN; LETTER; LIVER FAILURE; LIVER TOXICITY; LIVER TRANSPLANTATION; OBESITY; PRIORITY JOURNAL;

ADULT; ANTI-OBESITY AGENTS; FEMALE; HUMANS; LACTONES; LIVER FAILURE;

EID: 0035139206     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(00)00042-8     Document Type: Letter

References (4)

1. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. A randomized controlled trial
2. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study
3. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients
4. Clarifications, etiology and considerations of outcome in acute liver failure